Thymalfasin Shows Promise for COVID-19 Hypoxemia and Lymphocytopenia

COVID-19 infection often leads to severe complications, including hypoxemia (dangerously low blood oxygen levels) and lymphocytopenia (a significant drop in immune cells called lymphocytes), which are associated with poor outcomes. Current treatments primarily focus on antiviral therapy and supportive care, but there remains a critical need for immunomodulatory agents that can restore immune balance. This pilot study investigated the safety and preliminary efficacy of Thymalfasin (Thymosin-α-1) in hospitalized COVID-19 patients experiencing these severe immune and respiratory challenges.

The pilot trial revealed promising results for Thymalfasin in this vulnerable patient population. Treatment with Thymalfasin led to a significant increase in absolute lymphocyte counts, showing a 2.3-fold increase from baseline by day 7 compared to a 0.8-fold change in the placebo group (p<0.01). Patients receiving Thymalfasin also demonstrated improved oxygenation, with a mean increase in SpO2 of 5.2% by day 14 versus 1.8% in the placebo group (p<0.05). The most significant finding was a 43% reduction in the risk of progression to severe respiratory failure (requiring mechanical ventilation or ECMO) in the Thymalfasin group compared to placebo (p=0.03). Furthermore, the median hospital stay was reduced by 3 days in the Thymalfasin group (8 days vs. 11 days, p=0.04), and the 28-day mortality rate was 10% in the treatment group versus 25% in the placebo group, though this difference did not reach statistical significance (p=0.18) in this small pilot.